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Summary
The human genome encodes some hundreds of proteases. Many of these are well studied and 
understood with respect to their biochemistry, molecular mechanisms of proteolytic cleavage, 
expression patterns, molecular structure, substrate preferences and regulatory mechanisms, 
including their endogenous inhibitors. Moreover, precise determination of protease localisation 
within subcellular compartments, peri- and extracellular spaces has been extremely useful in 
elucidating biological functions of peptidases. This can be achieved by refined methodology as 
will be demonstrated herein for the cysteine cathepsins. Besides localisation, it is now feasible 
to study in situ enzymatic activity at the various levels of subcellular compartments, cells, tis-
sues, and even whole organisms including mouse.
Key words
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Introduction
Proteases belong to various families, i.e. the aspartic, cysteine, glutamic, met-
allo-, serine or threonine peptidases (Puente et al., 2003). However, some proteolytic 
enzymes remain unassigned and unclassified as yet. The most comprehensive over-
view of our present knowledge about proteases and their inhibitors can be found in 
the Merops database (Rawlings et al., 2010) at merops.sanger.ac.uk. This website is a 
valuable tool in approaching investigations on the biochemistry and molecular biol-
ogy of proteases throughout all kingdoms of living species such as Archaea, Eubacte-
ria and Eukaryota. In addition, viral proteases are included because they have gained 
increased attention in recent years due to their importance in a variety of infectious 
diseases. Inhibitors of proteases, the natural counter-parts of proteases, are important 
in safe-guarding mammalian cells, by regulating proteolytic enzymes in excess or in 
unwanted locations in diseased cells or tissues.
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This review article will focus on cysteine peptidases. In particular, we will discuss 
cysteine cathepsins that belong to the C1A subfamily of papain-like enzymes in clan 
CA (Rawlings et al., 1994; Chapman et al., 1997; Barrett et al., 2001; Reinheckel et al., 
2001; Turk et al., 2001; Nagler et al., 2003; Choe et al., 2006; Mohamed et al., 2006; 
Vasiljeva et al., 2007; Brix et al., 2008). Endogenous inhibitors of mammalian cysteine 
cathepsins comprise the family of cystatins (Barrett et al., 1981; Barrett et al., 1986; 
Bode et al., 1988; Abrahamson et al., 1994) and the propeptide-mimicking cytotoxic 
T-lymphocyte antigens (CTLA) -2a and -2b (Denizot et al., 1989). Cystatins function 
as intra- and extracellular proteins that integrate into the active site cleft of cysteine 
cathepsins in a wedge-shaped edge-like fashion (Abrahamson et al., 1987; Stubbs et 
al., 1990; Jenko et al., 2003). In contrast, the CTLAs bind to the active site of family 
C1 cysteine peptidases in reverse orientation, similar to their propeptides. This bind-
ing involves a chaperoning mechanism, also used during biosynthesis and trafficking 
of cysteine cathepsins, in order to retain the immature proenzyme in zymogen form 
until it reaches its target compartment (Guay et al., 2000; Wiederanders et al., 2000). 
The precise knowledge of the molecular structures of proteolytic enzymes and their 
endogenous inhibitors, along with the notion of their interactions in forming pro-
tease-inhibitor complexes in a reversible fashion, has stimulated increasing interest in 
using natural (e.g. E64) or synthetic inhibitors and other small molecule derivatives 
in order to target proteolytic activity (Barrett et al., 1982; Baruch et al., 2004). 
Cysteine cathepsins have been considered as useful targets to treat a large diver-
sity of disorders: atherosclerosis, cancer, rheumatoid and osteoarthritis, osteoporosis, 
neurodegenerative disorders such as Alzheimer’s disease and, more recently, inflam-
mation and obesity (Turk et al., 2006; Vasiljeva et al., 2007; Bromme et al., 2009). This 
impressive list of cysteine cathepsin involvement in pathological processes highlights 
their functional versatility, and the strategic move towards better tackling of specific 
protease inhibition has further entailed the development of invaluable tools to visual-
ize and image proteolytic functions of cysteine cathepsins, through the use of activity 
based probes (ABPs) (Jeffery et al., 2003; Baruch et al., 2004; Berger et al., 2004; Brix et 
al., 2005; Fonovic et al., 2007; Blum et al., 2008; Paulick et al., 2008). 
Visualization of proteolysis – a challenging task
Proteolysis is as complex as biology in general. Hence, elucidating expression pat-
terns of proteases and their inhibitors is a basic priority when approaching an under-
standing of protease functions. A variety of experimental set-ups have been well 
established in order to investigate the genome, transcriptome and proteome systems, 
and to compile a comprehensive list of proteases and inhibitors that enable cellular 
and tissue functions. 
Genome sequencing projects have been instrumental in learning more about the 
so-called degradome, the entire set of proteases expressed in a given organism (Lopez-
Otin et al., 2002; Puente et al., 2003; Quesada et al., 2009). Because proteases are regu-
lated by their endogenous inhibitors, these are also covered in The Mammalian Degra-
dome Database, provided at degradome.uniovi.es. Proteolytic enzymes are encoded by 
2% of the human genome, a huge proportion of all genes. Thus, it is hardly surprising 
that almost 90 different hereditary diseases known to date are derived from mutations 
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in protease genes (Lopez-Otin et al., 2008). Degradomics enable a systems biology anal-
ysis of all proteases, protease homologues and protease inhibitors through the use of 
DNA microarrays (Overall et al., 2006). This approach has been further taken to estab-
lish metadegradomics, which includes mass spectrometry for quantitative in vivo degra-
domics and the introduction of post-translational modifications (Doucet et al., 2008).
The next important step in understanding protease functions is to localize proteo-
lytic enzymes in an in situ context with their natural substrates and their endogenous 
inhibitors within cells and tissues. While this sounds like a classical domain of cell 
biologists, it became clear that a wider spectrum of disciplines is needed to provide 
the tools necessary for grasping the mammalian cell’s repertoire of proteases. With 
respect to the broader picture, it will be important to keep in mind that proteolysis 
is the most important post-translational protein modification process, because proteo-
lytic cleavage is irreversible, thus determining the fate of cells in their most critical 
turning point of deciding between life and death.
The study of protease functions must encompass determination of protease activi-
ties, which has often been achieved through the basic use of synthetic substrates in 
biochemical approaches. However, we are now entering an era where the more com-
plex tasks of monitoring substrate cleavage and tracking protease activities in intact 
cells (Tab. 1) are not only possible but reveal an overwhelming wealth of data. 
Spotting proteolytic enzymes at high resolution by immunolabeling for light and 
electron microscopy
Immunolocalization is the best known and most straightforward experimental 
approach to detect proteases in subcellular compartments and to localize secreted 
enzymes in tissues. Most protocols include fixation procedures that are based on for-
maldehyde fixation for light microscopical detection, or fixation with glutaraldehyde 
for electron microscopy. While both fixation techniques bear the clear advantage of 
being very well established and easy-to-use routines, it might be worthwhile consid-
ering an alternative fixation strategy, namely alcohol (ethanol or methanol) -based 
dehydration procedures. For example, it is well known that keratinocytes and oligo-
dendrocytes exhibit a strikingly different membrane lipid composition in compari-
son to cells such as fibroblasts. Accordingly, our own experience, as summarized in 
Tab. 2, has convinced us to compare methanol/acetone-based dehydration techniques 
carried out at low temperatures with paraformaldehyde-based protocols conducted at 
room temperature or at 37 °C, when visualizing cysteine cathepsins that are thought 
to reside within endo-lysosomal compartments of mammalian cells (Brix et al., 1996; 
Tepel et al., 2000; Linke et al., 2002b; Friedrichs et al., 2003; Buth et al., 2007; Jordans 
et al., 2009; Mayer et al., 2009; Vreemann et al., 2009; Tedelind et al., 2010). For the 
majority of cell types such as fibroblasts, thyroid epithelial cells, enterocytes or mac-
rophages, our preferred method is chemical cross-linking with mono- or bifunctional 
aldehydes, whereas keratinocytes are best treated with methanol. Other important 
measures that improve structural preservation are washing procedures before and 
after fixation, as well as paying attention to the composition of buffers used in com-
bination with certain fixatives. In our hands, calcium and magnesium-free phosphate 
buffered saline (CMF-PBS) is best combined with methanol/acetone solutions, where-
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as HEPES or PIPES are our preferred biogenic amine-based buffers used in combina-
tion with freshly prepared paraformaldehyde for fixation.
In this context, it is interesting to note that many researchers appear to be more 
concerned about the properties of specific antibodies rather than structural preserva-
tion of the primary antigen when choosing fixation protocols. Certainly, antibodies 
that are commercially available often prefer immunoidentification of their antigens in 
a specific context, such as in formaldehyde-fixed cell or tissue preparations without 
or after paraffin embedding, or as well exposed antigens and structurally well pre-
served molecules in frozen tissues. However, we further suggest taking the distinct 
lipid membrane composition of the cell type of interest into account. For illustration 
of the results achieved with identical antibodies in different cell types, examples are 
provided of cysteine cathepsin B localization in keratinocytes after methanol-acetone 
fixation (Fig. 1A), in thyroid carcinoma cells after fixation with paraformaldehyde 
(Fig. 1B), and in cryo-sections of mouse intestine tissue (Fig. 1C’). In all cases, the 
Table 1 – Sample preparation for various methods of cysteine cathepsin detection.
1. Transfection with vectors encoding fluorescent protein tagged protease
2. Fluid phase uptake to label endocytic compartments:
wash in PBS, incubate with 1 µM LysoTracker Red DND-99 in culture medium for 5 min 
(endosomes) or 30 min (lysosomes) at 37°C, chase in complete culture medium for 120 min 
– 24 h (lysosomes, only) at 37°C, wash in PBS, fix as desired, e.g. 3% PFA in PBS or HEPES 
for 30 min at 37°C
3. Activity Based Probes
• label pericellular proteases by incubation at 37°C with non-permeable ABP or protease 
substrate analogs, use inhibitors like E64d or CA-074d as control; 
• alternatively, incubate with cell-permeable ABP or protease substrate analogs, use 
inhibitors as control, incubate at 4°C to block endocytosis, then, wash and perform first 
minutes of fixation also at 4°C
• peri- and intracellular proteases can be labeled by incubation at 37°C with cell-
permeable ABP or protease substrate analogs, incubate with inhibitors as control; ABPs 
come as non-quenched or quenched probes; principle of labeling: ABPs are cleaved by 
active protease, releasing quenching group and resulting in covalently labeled protease
– non-quenched ABPs: fluorescence where probe binds, i.e. background could be a 
problem 
– quenched ABPs: fluorescence only where the probe binds specifically to active 
proteases, i.e. better signal-to-noise ratio is achievable
Notes:
Protease-specific inhibitors: 
E64 inhibits all cysteine peptidases, use at 1-5 µM; CA-074 inhibits cathepsin B specifically, use at 1-5 
µM; Z-FY(t-Bu)-DMK (Z-Phe-Tyr(t-Bu)-diazomethylketone) inhibits cathepsin L specifically, use at 1-5 µM
Activity Based Probes (ABPs):
NS-173 or NS-196 = rhodamine-conjugated or biotinylated cathepsin B-specific probe (Schaschke et al., 
2000), use at 500 nM in culture medium
DCG-04, e.g. Green-DCG-04, fluorophore-conjugated probes (Greenbaum et al., 2000), use at 500 nM in 
culture medium
GB-111 and GB-117, non-quenched and quenched probes (Blum et al., 2005), a variety of next genera-
tion ABPs have been synthesized recently (Blum et al., 2009), use at 500 nM in culture medium
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Figure 1 – Visualization of cathepsin B in cells and tissue using different fixation methods and indi-
rect immunofluorescence.
(A) Human HaCaT keratinocytes were fixed with methanol and acetone for 8 min each, at -20°C 
before immunolabeling with primary anti-cathepsin B and secondary, fluorophore-conjugated anti-
bodies (green). Nuclei were counter-stained with the nucleic acid-specific dye DRAQ5™ (red). Endo-
lysosomal (arrows), nuclear (arrowheads) and plasma membrane (open arrowheads) localizations of 
cathepsin B were readily observed. For further details on subnuclear labeling patterns, see (Tedelind 
et al., 2010).
(B) Human thyroid carcinoma KTC-1 cells were fixed with paraformaldehyde before immunolabeling 
with primary anti-cathepsin B and secondary fluorophore-conjugated antibodies (red). Nuclei were 
counter-stained with DRAQ5™ (blue) and cytoskeletal F-actin was visualized by FITC-phalloidin stain-
ing (green). Cathepsin B accumulated in the perinuclear Golgi region of thyroid carcinoma cells (bro-
ken arrow) and the protease was additionally sorted into vesicular structures spreading from the cell 
center in a star-like fashion (arrow), characteristic for vesicles transported along microtubules during 
protease trafficking with destination to endo-lysosomes. 
(C and C’) Mouse intestine tissue was paraformaldehyde-fixed before cryo-sectioning and immuno-
labeling with primary anti-cathepsin B and secondary fluorophore-conjugated antibodies (C’). Cath-
epsin B was detectable within endo-lysosomes of intestine epithelial cells (arrows) and the protease 
was abundantly immunolabeled within endocytic vesicles of cells in the lamina propria. 
In all three examples the same primary anti-cathepsin B-specific antibody was used to detect its dif-
ferently fixed antigen. Single channel and merged fluorescence micrographs in A and B are shown in 
false-colors; right hand panels in A and B and pictures in C and C’ depict single channel micrographs and 
phase contrast images as indicated. N, nucleus; scale bars represent 20 µm in A and B, and 50 µm in C’.
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cysteine cathepsin-containing structures could be easily visualized by fluorescence 
microscopy and are compared to well-preserved cellular structures as viewed in the 
corresponding phase contrast images (Fig. 1). 
Since cysteine cathepsins are redundantly expressed in both a ubiquitous and 
cell type-specific manner (Chapman et al., 1997; Nagler et al., 2003; Brix et al., 2008), 
it may also become important to simultaneously visualize other closely related 
enzymes. In such cases, we prefer to immunolabel in a consecutive fashion, meaning 
first to label the proteases present in small amounts with green fluorophores and then 
to visualize the more abundant proteins with employment of red fluorophores (Tepel 
et al., 2000; Jordans et al., 2009). This strategy ensures that the brightness of each fluo-
rophore as measured by its characteristic extinction coefficient and fluorescent quan-
tum yield is applied for the best detection of rare proteins as bright spots by the emit-
ted green fluorescence, on a usually more dimmed background fluorescence derived 
from labeling abundantly present proteolytic enzymes with red fluorophores. 
The results of such co-localization studies demonstrate that it is now possible to vis-
ualize even small amounts of rare nuclear cysteine cathepsin variants, which maximally 
constitute 5-10% of all cysteine peptidases in e.g. thyroid carcinoma cells (Tedelind et 
al., 2010), and which have escaped immunodetection for many decades. Nonetheless, 
with improved detection methods it is now possible to also study such rare proteases 
that are likely to be crucial for cell differentiation and cell fate determinations. 
Likewise, co-localization studies have allowed the investigation of protein compo-
sition of specific vesicles of endocytic compartments and have revealed the existence 
of different vesicle populations, such as in thyroid epithelial cells that are loaded with 
distinct sets of proteases (Tepel et al., 2000; Jordans et al., 2009; Tedelind et al., 2011). 
Such results are not at all trivial since they raise important questions; for example, 
how loading of vesicles with soluble enzyme cargo is achieved in mammalian cells. 
Clearly, thyroid epithelial cells are able to selectively recruit specific proteases that are 
present in different vesicle populations in particular biological contexts, for example 
in resting or thyroid stimulating hormone (TSH) -stimulated conditions (Brix et al., 
1996; Brix et al., 2001; Linke et al., 2002a; Linke et al., 2002b). This enables cells to 
fine-tune their protease cocktails in a subcellular compartment or even subcompart-
ment, so that they can cope with the necessity of degrading a huge variety of inter-
nalized molecules that are likely to differ in resting or stimulated conditions.
In order to detect cysteine cathepsins with high spatial resolution in various 
cellular compartments, immunoelectron microscopy is a useful tool. Visualiza-
tion of cysteine cathepsins with specific antibodies has been performed by classical 
approaches that involve post-Epon-embedding-labeling techniques or cryo-immuno- 
electron microscopy procedures as well as by rather unusual approaches which 
include immunolabeling of whole-mount preparations (Brix et al., 1996). 
Following protease tracks using fluorescent protein tagging experiments
Cysteine cathepsins are not exclusively present within endo-lysosomes; they are 
detectable in all compartments of the secretory route and in vesicles targeted to reach 
the compartments of the endocytic pathway. In addition, cysteine cathepsins are often 
actively secreted from cells in processes such as cell migration (Buth et al., 2004), tis-
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sue repair (Buth et al., 2007) or invasion of carcinoma cells (Mohamed and Sloane, 
2006), where the secreted enzymes are thought to be involved in ECM remodeling 
processes. Secreted cysteine cathepsins can further accumulate in structures such as 
caveolae (Cavallo-Medved et al., 2009) and they may also re-associate with the cell 
surface as shown in Fig. 1A. In peri-cellular locations such as in the vicinity of the 
apical plasma membrane of epithelial cells, cysteine cathepsins have been shown to 
contribute to limited proteolysis of molecules en-route to endosomes and lysosomes 
(Brix et al., 1996; Brix et al., 2001; Friedrichs et al., 2003; Buth et al., 2004; Mayer et al., 
2009; Vreemann et al., 2009; Dauth et al., 2011) and hence, act in the direct pericellu-
lar environment. In addition, rare variants of cysteine cathepsins have been detected 
which appear to serve key functions in unusual locations such as the mitochondrial 
matrix (Muntener et al., 2004) or the nucleus (Goulet et al., 2004; Ong et al., 2007; 
Duncan et al., 2008; Maubach et al., 2008; Tedelind et al., 2010). 
These observations illustrate that trafficking studies are important in elucidat-
ing the transport pathways of proteases within cells, which in turn provide clues to 
their function. Such studies are best performed by fluorescent protein tagging, which 
allows tracking of protease transport, from the rough endoplasmic reticulum (rER) 
where de novo-biosynthesis of the full-length forms occurs, to their main cellular 
destination within endo-lysosomes (Mach et al., 1994; Mort et al., 1997; Linke et al., 
2002a; Brix et al., 2008). One must bear in mind to tag the proteases in such a way 
that intrinsic protein sequences, essential for protein targeting and correct transport, 
will not become affected by introduction of the fluorescent protein-encoding sequenc-
es. Cysteine cathepsins can be tagged easily and without obvious mistargeting or 
loss-of-function effects when the green fluorescent protein (GFP) or other fluores-
cent proteins are attached to the C-terminus via a spacer peptide (Linke et al., 2002a; 
Katayama et al., 2008; Mayer et al., 2008). Cathepsin B has for example been localized 
to endo-lysosomes through visualization of the eGFP-tagged chimeric protein (Linke 
et al., 2002a) in thyroid carcinoma KTC-1 cells (Tedelind et al., 2011), in the absence or 
presence of LysoTracker® that accumulates in endo-lysosomal compartments (Fig. 2). 
A variety of fluorescent proteins are available, some of which might also be useful in 
studying the precise timing of transport reactions, while others might be instrumen-
tal in determining interactions of proteases with substrates or other partners, such 
as split GFP (Waldron et al., 2008) or fluorescence resonance energy transfer (FRET) 
approaches, which are achievable and in use (Chudakov et al., 2010).
However, fluorescent protein tagging can be used as well to study secretion path-
ways of the zymogen forms along the secretory route in particular cells, e.g. cancer 
cells (Moin et al., 2000; Sameni et al., 2001; Mohamed and Sloane, 2006), or to analyze 
the strategies that epithelial cells use to recruit mature cysteine cathepsins out of late 
endosomes/lysosomes for retrograde trafficking and secretion into the extracellular 
space (Linke et al., 2002a; Linke et al., 2002b; Brix et al., 2008; Dauth et al., 2011). Inter-
estingly, many cell types have been recognized as being competent in secretion of endo-
lysosomal enzymes (Brix et al., 1994; Andrews et al., 2000; Brix et al., 2008). However, 
the precise transport pathways are not always studied in sufficient detail. Macrophages 
and dendritic cells are especially exceptional in the transport of proteases because they 
need to adapt quickly to situations such as infection and inflammation, where they 
serve as first-line defence and antigen-presenting cells respectively (Bogyo and Ploegh, 
1998; Honey and Rudensky, 2003; Beers et al., 2005; Hsing et al., 2005).
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Moreover, fluorescent protein-tagged cysteine cathepsins might become useful in 
determining the exact timing and to quantify the extent of lysosomal membrane rup-
ture. That is, for instance, essential for release of mature cathepsin B into the cytosol 
which eventually leads to induction of apoptotic cell death by an alternative intrin-
sic induction pathway due to Bid-cleavage (Houseweart et al., 2003; Turk et al., 2009) 
and may be involved in killing of tumor cells by irradiation to induce lysosomal 
burst (Kroemer and Jaattela, 2005). 
Caught in the act – monitoring protease activities and substrate cleavage in cells 
and tissues
From the above, it becomes clear that proteases are a group of extremely ver-
satile enzymes that function in all possible locations within and outside cells. The 
classical view of cysteine cathepsins purely as lysosomal enzymes is now clearly 
outdated. Therefore, strategies are needed to visualize and image proteases in sites 
of action (Baruch et al., 2004; Blum et al., 2005; Brix and Jordans, 2005; Brix et al., 
2008; Blum et al., 2009). 
A variety of such strategies can include enzyme cyto- and histochemistry 
encompassing various photo conversion methods (Spiess et al., 1994). However, the 
principal possibility of combining immunolabeling with enzyme cytochemistry has 
Figure 2 – Localizing cathepsins in living cells using enhanced green fluorescent protein tags.
Human thyroid carcinoma cells were transfected with a vector coding for cathepsin B-eGFP chimeras (A, 
green). One day post-transfection, the vital stain LysoTracker was applied at 37°C in complete culture medi-
um for fluid phase uptake and accumulation within endo-lysosomes in the perinuclear region (B, red). Cells 
were viewed through live cell imaging with a confocal laser scanning microscope. Thyroid carcinoma cells 
transiently expressing cathepsin B-eGFP displayed a vesicular staining pattern of the GFP-tagged cathepsin B 
peptidase (green) in a pattern characteristic for endo-lysosomal compartments in the peri-nuclear region (A 
and B, arrows). The vesicles containing eGFP-tagged cathepsin B were partially co-localized with those that 
acquired the fluid phase marker (B, yellow as a result of overlapping green and red signals), indicating that 
GFP-tagging did not interfere with protease transport to endo-lysosomes. 
Single channel and merged fluorescence micrographs in A and B are shown in false-colors; right hand panel 
in B depicts corresponding single channel micrographs and phase contrast as indicated. N, nucleus; scale 
bars represent 20 µm in A and 50 µm in B. 
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rarely been realized (Brix et al., 1996). The procedures that may be used to precisely 
determine the locations of cysteine cathepsin actions are summarized in Fig. 3. The 
protocols for detection of cysteine cathepsins are detailed in Tabs 1 to 3, and can be 
varied such that specific substrates in combination with enzyme-specific inhibitors 
may be used for ultrastructural detection, which are then verified by post-embed-
ding immunolabeling procedures (Brix et al., 1996; Brix et al., 2008). Furthermore, 
a variety of antibodies can be tested by immunogold labeling techniques. However, 
those protocols bear the obvious disadvantage of inducing alterations of protease 
activities that may be caused by harsh fixation methods and other drastic chemical 
treatments of cells.
Hence, protease activities are best investigated by fluorescence microscopy meth-
ods that are optimal for exclusive use in living cells. In former times, fluorescently 
labelled extracellular matrices have been used to track substrate cleavage during pro-
cesses such as cell migration (Friedl et al., 2000; Jedeszko et al., 2008; Cavallo-Medved 





cell culture, e.g. on cover glasses X X
PBS X X
fixation: 1% PFA in PBS, 20 min, RT --- X
PBS --- X
reactivation: 
reaction buffer (RB = 0.2 M ammonium acetate, 0.125 mM 
ß-mercaptoethanol, 0.1 mM EDTA-Na2, 
pH 6.2 or pH 7.2 with 0.4 M Na2HPO4), 5 min, 40°C without O2
X X
reaction at 40°C without O2 for 15 - 60 min:
1 mM protease-specific substrate coupled to 4-methoxy-
ß-naphthylamine in RB + 0.5 – 1 mM 2-hydroxy-5-
nitrosalicylaldehyde (NSA); controls: 1 mM E64 in RB, or omit 
substrate from RB + NSA
X X
PBS or CMF-PBS X X
fixation: 1% PFA in PBS, 20 min, RT X ---
PBS X ---
ddH2O X X
mounting in 33% glycerol, 14% mowiol in 200 mM Tris (pH 8.5) X X
view at excitation 488 nm X X
X, step required; ---, step not required; RT, room temperature; O2, oxygen; ddH2O, double distilled water
Protease-specific substrates
cathepsin B: 0.5 – 1 µM Z-Arg-Arg-4MßNA ± CA-074 (pH 6.0 – optimum); controls with E64
cathepsin K: 0.5 – 1 µM Z-Gly-Pro-Arg-4MßNA ± 10 µM CA-074; controls with E64
cathepsin L: 0.5 – 1 µM Z-Phe-Arg-4MßNA ± 1.5 µM CA-074 (pH 5.5 – optimum); controls with CA-074 + 
Z-FY(t-Bu)-DMK
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et al., 2009). A number of small molecules are now available that have accelerated 
the field of cysteine cathepsin biology significantly in recent years (Greenbaum et al., 
2000; Greenbaum et al., 2002; Blum, 2008; Blum et al., 2009). The basic idea of activ-
ity based probes (ABPs) is the synthesis of small molecules that can easily penetrate 
biological membranes (see, Tab. 1), therefore reaching all potential locations of pro-
teolytic enzymes within cells and tissues. 
In general, ABPs bear a so-called warhead, i.e. they are functionalized to bind to 
only one group of proteases, because the mechanism of action is specific targeting 
of ABPs to one family of enzymes (Liu et al., 1999; Kidd et al., 2001; Baruch et al., 
2004; Kato et al., 2005; Sieber et al., 2006; Sexton et al., 2007; Wright et al., 2009; Yang 
et al., 2009). Upon binding, ABPs are cleaved since most of them represent substrate 
analogs, thereby attaching themselves covalently to the targeted proteases. ABPs are 
additionally functionalized with fluorophores, iodinatable groups, biotin moieties 
Figure 3 – Schematic representation of experimental strategies for imaging of cysteine cathepsin functions.
An appropriate choice from the selection of detection methods available for cysteine peptidase localization 
is dependent on factors such as the nature of the experimental question, type of specimen and specimen 
preparation. Most established protocols of indirect immunofluorescence employ the use of antibodies which 
can effectively detect both zymogens (A and F) and active cathepsins (B – E and G – K). Cathepsin activity 
can be visualized through the use of substrate analogs that are cleaved upon encountering active protease 
with the leaving groups precipitating at the spot of enzymatic activity (B and G). Leaving groups may be vis-
ualized through signal enhancement by incubation with nitrosalicyladehyde in fluorescence microscopy, or 
pararosanilin and OsO4 in electron microscopy (Brix et al., 1996). Active cysteine cathepsins in complex with 
their endogenous inhibitors such as the cystatins, can be detected using cystatin-specific antibodies (C and 
H). A very valuable tool for detecting active cathepsins at their sites of action is the use of quenched (D and 
J) or non-quenched activity-based probes (ABP; E and K). Quenched ABPs are designed to mimic the natural 
substrate and covalently interact with the protease in its active site, whereby the fluorescent signal is gener-
ated upon proteolytic cleavage. Non-quenched ABPs are fluorescent before interacting covalently with the 
active protease in a 1-to-1 ratio, thereby fluorescently highlighting enzymatic activities on the spot (E and 
K; Brix and Jordans, 2005). Another useful approach of studying cathepsins in living cells is the use of GFP-
tagged chimeras, which constitutively track the position of the proteins regardless of whether immature (F) 
or enzymatically active (G – K) proteases are tagged with GFP (Brix et al., 2008). GFP fusion at the C-terminus 
of cysteine cathepsin B has been shown not to interfere with protease trafficking. GFP tagging of proteases 
can be combined with immunofluorescence or enzyme cytochemical or ABP labelings of all kinds (F – K).
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etc., which are attached to the opposite end of the small molecule backbone. Hence, 
ABPs target protease families rather than individual enzymes as shown for the mem-
brane permeable and fluorophore-conjugated DCG-04 that visualizes active cysteine 
peptidases in human keratinocytes (Fig. 4B). An alternative approach combines 
Figure 4 – Employment of activity-based probes for spotting enzymatic activity of cathepsins at their sites of 
action in vivo and in situ.
(A) Live cell imaging through confocal fluorescence and phase contrast microscopy of human HaCaT 
keratinocytes after treatment with a membrane impermeable, biotinylated cathepsin B-specific activity 
based probes (ABP; Schaschke et al., 2000) and incubation with fluorophore-conjugated streptavidin (green), 
visualizing cathepsin B activity at the cell surfaces and at junctions between neighboring cells (open arrow-
heads). 
(B) Live cell imaging through confocal fluorescence and phase contrast microscopy of human HaCaT 
keratinocytes after treatment with a membrane permeable, fluorophore-conjugated cysteine peptidase-
specific ABP (Greenbaum et al., 2000), visualizing cathepsin B activity within endo-lysosomes (green; arrows) 
accumulating in the perinuclear region of HaCaT cells. 
(C and C’) Confocal fluorescence images (green) merged with corresponding phase contrast micrographs 
(dark blue) of cryosections prepared from paraformaldehyde-fixed mouse intestine tissue and after incuba-
tion with a cathepsin B-specific ABP (green; Schaschke et al., 2000). The cryosections were pre-incubated 
with freshly prepared L-cysteine for re-activation of cysteine peptidase activity before ABP treatment; E64 
incubation served as a control for ABP-specificity as the fluorescence signal within endo-lysosomes (arrows 
in C’) was clearly diminished in inhibitor-competed ABP stainings of cryosections (C). A number of fluores-
cent dots in cells present in the lamina propria are most likely due to lipofuscins accumulating within cells, 
e.g. macrophages or neutrophils.
Merged pictures of single fluorescence channels with corresponding phase contrast micrographs are shown 
in false-colors; right hand panels depict corresponding single channel micrographs and phase contrast 
images. N, nucleus; scale bars represent 10 µm in A, 20 µm in B, and 50 µm in C and C’. 
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propeptide-like with substrate-like binding properties in a synthetic small molecule 
(Schaschke et al., 2000). These probes are suitable in targeting individual enzymes 
in larger families of related proteases. For instance, a cathepsin B-specific probe 
has been designed which is able to clearly distinguish between the most abundant-
ly expressed cathepsins B and L by an impressive factor of 2,000 (Schaschke et al., 
2000; Schaschke et al., 2002). The fluorophore-conjugated ABP specific for cathepsin 
B, NS173, enabled the visualization of active, plasma membrane associated cathepsin 
B in human keratinocytes (Fig. 4A), and it can be used additionally for visualization 
of active cathepsin B in situ in mouse intestine (Fig. 4C´) while pre-incubation with 
the cysteine cathepsin inhibitor E64 serves as a control for probe selectivity (Fig. 4C). 
Quenched ABPs provide better signal-to-noise ratios than non-quenched probes 
because they become fluorescent only upon cleavage and covalent attachment to the 
target protease (Blum et al., 2005; Brix and Jordans, 2005; Blum et al., 2007; Blum et 
al., 2009). This elegant approach has now reached as far as the design of ABPs for 
diagnostic use in mouse (Blum et al., 2007; Blum et al., 2009). The long-term goal is to 
utilize them in translational approaches of rational drug design as therapeutics. 
These most promising features of ABPs point to their future applications as use-
ful tools to visualize excess protease activities and to even treat diseases like cancer 
at the molecular level. However, the molecular features of ABPs and their mecha-
nism of action also bear a serious disadvantage to this approach. Namely, ABPs act 
as inhibitors of the targeted proteases. ABPs bind and covalently attach to their target 
proteases in a one-to-one fashion. Hence, for therapy they must be used in extremely 
high concentrations, thereby increasing the risk of toxicity and induction of off-target 
effects. On one hand, since they are protease inhibitors, treatment of a cell with ABPs 
may elegantly target protease activities; on the other hand, a pharmacological knock-
down can be easily produced. 
In future, ABPs and related molecules could become as useful as gene knock-
down or knock-out strategies in altering the composition of proteolytic networks on 
a long-term basis. It would then also be possible to challenge protease activities and 
actions by using animal models of various diseases. The goal is to target, inhibit or 
initiate protease activities, in order to learn more about their true biological signifi-
cance as enzymes mediating quick cuts that irreversibly change the fate of proteins. 
Conclusions and Perspectives
Tracking and localizing proteases in living cells and co-localizing proteases with their 
natural substrates in an entire organism is our ultimate objective in specifying the sig-
nificance of proteolysis in vivo (see, Fig. 3). This aim is not far away. Numerous experi-
mental achievements have demonstrated that pharmacological inhibition, gene targeting 
through knock-outs, knock-ins, transgenic over-expression or knock-downs, and combi-
nations with imaging studies of protease functions in living cells have been conducive in 
answering several important questions. These include, but are not limited to, issues on 
the in vivo importance of a certain protease in any given biological context. To this end, 
we will continue in our aim of clarifying how post-translational proteolytic modifica-
tions are involved in biological processes during development, adulthood and in ageing. 
Proteases encoding two percent of the entire human genome must be expressed for fun-
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damentally crucial reasons - to enable the molecular basis of decision-making processes 
of cells in tissues and in all conditions of life, disease, repair and death. 
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